Literature DB >> 3278419

The repopulation capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in rhesus monkeys.

W R Gerritsen1, G Wagemaker, M Jonker, M J Kenter, J J Wielenga, G Hale, H Waldmann, D W van Bekkum.   

Abstract

Complement-mediated lysis of (subsets of) T lymphocytes in bone marrow grafts is increasingly used to prevent acute graft-versus-host disease in human bone marrow transplant recipients, especially in case of major immunogenetic disparity between donor and recipient. Since T lymphocyte depletion has resulted in an increased frequency of allogeneic engraftment failures, its effect on hemopoietic reconstitution was measured in rhesus monkeys. The reactivity patterns of commonly used types of antihuman T lymphocyte monoclonal antibodies (MCAs) with rhesus monkey lymphocytes was analyzed using a double-label cytofluorometry technique and found to be very similar to those with human lymphocytes. The antibodies investigated included CAMPATH-1 (recognizing an antigen present on virtually all lymphocytes and monocytes), OKT4 + 4a (CD4, helper/inducer T lymphocytes), B9 (CD8, suppressor/cytotoxic T lymphocytes), WT-1 (CD7, pan-T), and anti-DR MCAs as stem cell toxic controls. Their possible toxicity to hemopoietic stem cells was studied by using a semiquantitative autologous regeneration assay. Cytotoxic lysis of cells in the bone marrow grafts reacting with the T lymphocyte purging MCAs did not result in delayed regeneration compared to untreated autologous grafts. It is concluded that T lymphocyte depletion using anti-T-lymphocyte MCAs does not influence the repopulating capacity of an autologous bone marrow graft.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278419     DOI: 10.1097/00007890-198802000-00010

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells.

Authors:  V W van Beusechem; A Kukler; P J Heidt; D Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 2.  Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Authors:  Peter J Bugelski; Pauline L Martin
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells.

Authors:  D M Bodine; K T McDonagh; S J Brandt; P A Ney; B Agricola; E Byrne; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 4.  CAMPATH: from concept to clinic.

Authors:  Herman Waldmann; Geoff Hale
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 5.  Alemtuzumab in stem cell transplantation.

Authors:  Geoff Hale
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.